Equillium (EQ) Cash from Financing Activities (2018 - 2026)
Equillium (EQ) reported Cash from Financing Activities of $35.3 million for Q1 2026, up 38741.76% year-over-year from N/an in Q1 2025, and up 12389.75% quarter-over-quarter from $283000.0 in Q4 2025.
Equillium (EQ) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Cash from Financing Activities data on file, last reported at $35.3 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $35.3 million, up 38741.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.7 million (up 26929.63% YoY), and the FY2025 annual result was $30.4 million, up 18453.05% from the prior year.
- Cash from Financing Activities climbed to $35.3 million in Q1 2026 per EQ's latest filing, from $283000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $35.3 million in Q1 2026 and troughed at -$7.6 million in Q2 2023.
- A 5-year average of $5.0 million and a median of $73000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities sank 702.67% in 2022, then jumped 38741.76% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at -$1.4 million in 2022, then soared by 105.83% to $79000.0 in 2023, then dropped by 7.59% to $73000.0 in 2024, then jumped by 287.67% to $283000.0 in 2025, then surged by 12389.75% to $35.3 million in 2026.
- Business Quant data shows EQ's Cash from Financing Activities at $35.3 million in Q1 2026, $283000.0 in Q4 2025, and $30.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | 35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.35 Mn |
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 283,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 30.07 Mn |
| Sep 30, 2025 | 30.07 Mn |
| Jun 30, 2025 | -16,000.00 |
| Jun 30, 2025 | -16,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Sep 30, 2023 | -260,000.00 |
| Sep 30, 2023 | -260,000.00 |
| Jun 30, 2023 | -7.62 Mn |
| Jun 30, 2023 | -7.62 Mn |
| Mar 31, 2023 | -1.43 Mn |
| Mar 31, 2023 | -1.43 Mn |